Study warns of high Medicare costs for semaglutide even with restrictive CVD definition

If Medicare Part D narrowly defines cardiovascular disease, the majority of patients would remain ineligible while new federal spending could still exceed $10 billion

Idorsia plans further job cuts and asset sale in latest cost-saving measures – Pharmaceutical Technology

Shares in Idorsia opened 17.5% higher following the news of its restructure. Image credit: Shutterstock / Taljat David. Idorsia is on the restructuring path again

November 27, 2024

Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225 – Biotech Investments

Eckert & Ziegler SE / Key word(s): Alliance Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225 13-Nov-2024 /

November 14, 2024

Investigating IDO1 and PDL1: Key immune checkpoints in cutaneous leishmaniasis research

In this Interview News Med talks to Dr. Nidhi Dey about immune checkpoints IDO1 and PDL1 and how they relate to cutaneous leishmaniasis research.

December 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.